EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain
Background: Limited real-world data exist on managing locally advanced/metastatic urothelial carcinoma (la/mUC), crucial for predicting outcomes and integrating new treatments. This study explores la/mUC in Northern Spain. Methods: Retrospective observational analysis from 16 hospitals across 12 pro...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | ESMO Real World Data and Digital Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949820124000419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140988464431104 |
|---|---|
| author | R. Fernández Rodríguez N. Sagastibeltza E. Pujol Obis N. Lainez Milagro R. Sánchez-Escribano M. Martínez Kareaga J.A. Verdún Aguilar M. Arruti Ibarbia M. Pumares González T. de Portugal Fernández del Rivero A. Lacalle Emborujo I. Gil Arnaiz A. Pereira-Elorrieta C. Álvarez Fernández I. Duran |
| author_facet | R. Fernández Rodríguez N. Sagastibeltza E. Pujol Obis N. Lainez Milagro R. Sánchez-Escribano M. Martínez Kareaga J.A. Verdún Aguilar M. Arruti Ibarbia M. Pumares González T. de Portugal Fernández del Rivero A. Lacalle Emborujo I. Gil Arnaiz A. Pereira-Elorrieta C. Álvarez Fernández I. Duran |
| author_sort | R. Fernández Rodríguez |
| collection | DOAJ |
| description | Background: Limited real-world data exist on managing locally advanced/metastatic urothelial carcinoma (la/mUC), crucial for predicting outcomes and integrating new treatments. This study explores la/mUC in Northern Spain. Methods: Retrospective observational analysis from 16 hospitals across 12 provinces. The study population included adult patients diagnosed with la/mUC (1 January 2007-31 December 2019). Median overall survival and progression-free survival were determined using the Kaplan–Meier method. Results: A total of 1230 patients were included, 83% were males, median age was 68, and 70% had a smoking history. The most common primary tumor was bladder (89.2%) followed by renal pelvis (6.4%), ureter (4.3%), and urethra (0.1%) and most of them (91%) were pure urothelial tumors. Cystectomy was the predominant treatment of localized disease (69%) and 30% received perioperative chemotherapy. Twenty-four percent of la/mUC patients never received systemic therapy and out of 934 patients treated with first-line (1L) therapy, 55% were fit for cisplatin. Progression to further lines of treatment was poor, only 53% (n = 492) progressed to receive a second line and 22% (n = 209) to a third line. Median overall survival (95% confidence interval) was 12.2 (11.3-12.9) months for the entire cohort and 14.5 and 10.8 months for patients who received first-line cisplatin or carboplatin-based chemotherapy, respectively. No unexpected toxicity was reported. Conclusions: This Spanish real-world data analysis echoes previous findings and highlights unmet needs, including the proportion of patients not receiving systemic treatment and the limited progression to subsequent lines of therapy, hampering access to new effective treatments. |
| format | Article |
| id | doaj-art-2ca565a136084ce48ce7bc93e4ebbdc0 |
| institution | OA Journals |
| issn | 2949-8201 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Real World Data and Digital Oncology |
| spelling | doaj-art-2ca565a136084ce48ce7bc93e4ebbdc02025-08-20T02:29:38ZengElsevierESMO Real World Data and Digital Oncology2949-82012024-12-01610006310.1016/j.esmorw.2024.100063EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern SpainR. Fernández Rodríguez0N. Sagastibeltza1E. Pujol Obis2N. Lainez Milagro3R. Sánchez-Escribano4M. Martínez Kareaga5J.A. Verdún Aguilar6M. Arruti Ibarbia7M. Pumares González8T. de Portugal Fernández del Rivero9A. Lacalle Emborujo10I. Gil Arnaiz11A. Pereira-Elorrieta12C. Álvarez Fernández13I. Duran14Medical Oncology Department, Hospital Universitario de Cruces & Instituto Oncológico IMQ Bilbao – Clínica IMQ Zorrotzaurre, BizkaiaMedical Oncology Department, Hospital Universitario Donostia-OSI Donostialdea, DonostiaHospital Clínico Universitario Lozano Blesa, ZaragozaHospital Universitario de Navarra, PamplonaHospital Clínico Universitario de Valladolid, ValladolidHospital Universitario de Araba – Txagorritxu, Vitoria-GasteizHospital Universitario Miguel Servet, Zaragoza & Hospital de Alcañiz, TeruelHospital Galdakao-Usansolo, BizkaiaHospital Universitario de Burgos, BurgosComplejo Asistencial de Zamora, ZamoraHospital San Pedro, LogroñoHospital Reina Sofia de Tudela, NavarraInstituto de investigación Sanitaria Valdecilla (IDIVAL), SantanderHospital Universitario Central de Asturias, OviedoInstituto de investigación Sanitaria Valdecilla (IDIVAL), Santander; Hospital Universitario Marqués de Valdecilla, Santander, Spain; Correspondence to: Dr Ignacio Duran, Hospital Universitario Marqués de Valdecilla, Edificio Sur. Consulta 277, Avda. Valdecilla s/n, 39008 Santander, Spain. Tel: +34-942-202515Background: Limited real-world data exist on managing locally advanced/metastatic urothelial carcinoma (la/mUC), crucial for predicting outcomes and integrating new treatments. This study explores la/mUC in Northern Spain. Methods: Retrospective observational analysis from 16 hospitals across 12 provinces. The study population included adult patients diagnosed with la/mUC (1 January 2007-31 December 2019). Median overall survival and progression-free survival were determined using the Kaplan–Meier method. Results: A total of 1230 patients were included, 83% were males, median age was 68, and 70% had a smoking history. The most common primary tumor was bladder (89.2%) followed by renal pelvis (6.4%), ureter (4.3%), and urethra (0.1%) and most of them (91%) were pure urothelial tumors. Cystectomy was the predominant treatment of localized disease (69%) and 30% received perioperative chemotherapy. Twenty-four percent of la/mUC patients never received systemic therapy and out of 934 patients treated with first-line (1L) therapy, 55% were fit for cisplatin. Progression to further lines of treatment was poor, only 53% (n = 492) progressed to receive a second line and 22% (n = 209) to a third line. Median overall survival (95% confidence interval) was 12.2 (11.3-12.9) months for the entire cohort and 14.5 and 10.8 months for patients who received first-line cisplatin or carboplatin-based chemotherapy, respectively. No unexpected toxicity was reported. Conclusions: This Spanish real-world data analysis echoes previous findings and highlights unmet needs, including the proportion of patients not receiving systemic treatment and the limited progression to subsequent lines of therapy, hampering access to new effective treatments.http://www.sciencedirect.com/science/article/pii/S2949820124000419disease managementbladder cancerimmunotherapyreal-world data |
| spellingShingle | R. Fernández Rodríguez N. Sagastibeltza E. Pujol Obis N. Lainez Milagro R. Sánchez-Escribano M. Martínez Kareaga J.A. Verdún Aguilar M. Arruti Ibarbia M. Pumares González T. de Portugal Fernández del Rivero A. Lacalle Emborujo I. Gil Arnaiz A. Pereira-Elorrieta C. Álvarez Fernández I. Duran EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain ESMO Real World Data and Digital Oncology disease management bladder cancer immunotherapy real-world data |
| title | EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain |
| title_full | EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain |
| title_fullStr | EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain |
| title_full_unstemmed | EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain |
| title_short | EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain |
| title_sort | ebano study real world data from patients with locally advanced metastatic urothelial carcinoma la muc in northern spain |
| topic | disease management bladder cancer immunotherapy real-world data |
| url | http://www.sciencedirect.com/science/article/pii/S2949820124000419 |
| work_keys_str_mv | AT rfernandezrodriguez ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT nsagastibeltza ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT epujolobis ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT nlainezmilagro ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT rsanchezescribano ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT mmartinezkareaga ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT javerdunaguilar ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT marrutiibarbia ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT mpumaresgonzalez ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT tdeportugalfernandezdelrivero ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT alacalleemborujo ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT igilarnaiz ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT apereiraelorrieta ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT calvarezfernandez ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain AT iduran ebanostudyrealworlddatafrompatientswithlocallyadvancedmetastaticurothelialcarcinomalamucinnorthernspain |